

Supplementary Table 11. Detailed genomic characteristics for each case of NSCLC with oncogenic / likely oncogenic *MET* tyrosine kinase domain (TKD) mutations in cohort #1.

| Treatment annotations | Patient ID | Histologic subtype | MET TKD mutation | <i>MET</i> amplification | Other driver alterations |
|-----------------------|------------|-----------------------------|------------------|--------------------------|--------------------------|
| Unknown | #1 | Lung squamous | D1228N | NA | No |
| Unknown | #2 | Lung Adenocarcinoma | D1228N | <i>MET</i> amplified | CD74-ROS1 |
| Unknown | #3 | Lung Adenocarcinoma | H1094D | NA | No |
| Unknown | #4 | Lung squamous | H1094R | No | No |
| Unknown | #5 | Lung Adenocarcinoma | H1094Y | NA | No |
| Unknown | #6 | Lung Adenocarcinoma | H1094Y | NA | No |
| Unknown | #7 | Lung Adenocarcinoma | H1094Y | No | KRAS G12V |
| Unknown | #8 | Lung Adenocarcinoma | M1250T | No | KRAS G12C |
| Unknown | #9 | Lung Adenocarcinoma | H1094D | No | No |
| Unknown | #10 | Lung Adenocarcinoma | V1220L | No | KRAS G12C |
| Unknown | #11 | Lung Adenocarcinoma | Y1230H | <i>MET</i> amplified | No |
| Unknown | #12 | Lung Adenocarcinoma | Y1230N | <i>MET</i> amplified | No |
| Unknown | #13 | Lung Adenocarcinoma | Y1235H | No | No |
| Unknown | #14 | Lung Adenocarcinoma | D1228N | No | KRAS G12F |
| Unknown | #15 | Lung Adenocarcinoma | D1228N | No | CD74-ROS1 |
| Known | #16 | Lung squamous | D1228H | <i>MET</i> amplified | No |
| Known | #17 | Lung Adenocarcinoma | D1228N, Y1230H | <i>MET</i> amplified | No |
| Known | #18 | Lung Adenocarcinoma | D1228V | <i>MET</i> amplified | EGFR exon 19 deletion |
| Known | #19 | Lung Adenocarcinoma | D1228Y | <i>MET</i> amplified | EGFR L858R |
| Known | #20 | Lung Adenocarcinoma | F1200I | No | No |
| Known | #21 | Poorly Differentiated NSCLC | H1106D | No | No |
| Known | #22 | Lung Adenocarcinoma | V1188I | No | No |
| Known | #23 | Lung Adenocarcinoma | V1220I | No | No |
| Known | #24 | Lung Adenocarcinoma | V1220L | No | KRAS G12C |
| Known | #25 | Lung Adenocarcinoma | Y1230H | <i>MET</i> amplified | No |
| Known | #26 | Lung Adenocarcinoma | D1228G | No | HLA-DRB1-MET fusion |
| Known | #27 | Lung Adenocarcinoma | D1228H | No | KRAS G12C |
| Known | #28 | Lung Adenocarcinoma | D1228N | No | EGFR exon 19 deletion |
| Known | #29 | Lung Adenocarcinoma | D1228N | No | CD74-ROS1 |
| Known | #30* | Lung Adenocarcinoma | D1228N | No | KLC4-ALK fusion |
| Known | #31 | Lung Adenocarcinoma | D1228N | No | CD74-ROS1 |
| Known | #32 | Lung Adenocarcinoma | D1228N | No | EGFR L858R |
| Known | #33 | Lung Adenocarcinoma | H1094R | No | KRAS Q61H |
| Known | #34 | Lung Adenocarcinoma | H1094Y | <i>MET</i> amplified | EGFR exon 19 deletion |
| Known | #35 | Lung Adenocarcinoma | H1094Y | No | No |
| Known | #36 | Lung Adenocarcinoma | H1094Y | No | EGFR exon 19 deletion |
| Known | #37 | Lung Adenocarcinoma | H1094Y | No | EGFR exon 19 deletion |
| Known | #38 | Lung Adenocarcinoma | H1094Y | No | KRAS G12A |
| Known | #39 | Poorly Differentiated NSCLC | H1094Y | No | No |
| Known | #40 | Lung Adenocarcinoma | L1195V | <i>MET</i> amplified | EGFR exon 19 deletion |
| Known | #41 | Lung Adenocarcinoma | L1195V | No | No |
| Known | #42 | Lung Adenocarcinoma | N1100S | No | No |
| Known | #43 | Lung Adenocarcinoma | Y1230C, D1228N | <i>MET</i> amplified | EGFR exon 19 deletion |
| Known | #44 | Lung Adenocarcinoma | Y1230C, Y1230H | <i>MET</i> amplified | EGFR exon 19 deletion |

In red: cases with *MET* TKD mutations detected *de-novo*

In blue: cases with *MET* TKD mutations detected after *MET* TKIs

In green: cases with *MET* TKD mutations detected after *EGFR* TKIs

In purple: cases with *MET* TKD mutations detected after *ROS1* TKIs

*Not available NGS at baseline therefore was not possible to understand whether MET D1228N arose after ALK TKIs or was present *de-novo* (Patient ID: #30)